Adults previously infected with SARS-CoV-2 develop short-term immunity and may have increased reactogenicity to COVID-19 vaccines.
Providers should consider counselling on adverse effects for previously infected individuals prior to vaccination.
Study: academic.oup.com
Providers should consider counselling on adverse effects for previously infected individuals prior to vaccination.
Study: academic.oup.com
Evidence shows people with prior SARS-CoV-2 infection develop a more robust immune response even after a single dose compared to infection-naive individuals. This response has led to concerns that vaccination of these individuals may result in higher incidences of adverse events.
Health events began in the first 24 hrs. of dose 1 for the majority, regardless of infection status or vaccine type. However, a larger proportion of mRNA recipients previously infected (75 - 80%) had onset within the first 24 hrs. compared to just over 50% of uninfected patients.
For all 3 doses, health events that prevent daily activities or require medical care were more likely to occur in the 1st week following vaccination in individuals with a prior moderate to severe SARS-CoV-2 infection and occurred more frequently after mRNA-1273 than BNT162b2.
Reassuringly, the most frequently reported AEFI symptoms were fever, myalgia, and headache, were self-limited in nature, and resolved within 24 to 72 hours after vaccination. Less than 1% required emergency care or hospitalization.
Other studies have identified more severe postvaccine symptoms occurring more frequently among people with previous SARS-CoV-2 infection only after the first dose of COVID-19 vaccine and less severe, but more frequent, reactions after the second dose.
Additionally, the duration between doses in Canada (median of 2 months for the primary series and at least 6 months for the booster dose) was greater than that used in other countries. This longer duration may also have reduced reactogenicity.
In this large study, health events were increased in the week following vaccination with BNT162b2, mRNA-1273, and ChAdox1-S vaccines in individuals with prior SARS-CoV-2 infection and this association increased according to infection severity - suggestive of a dose response.
Conclusions:
Providers should consider additional vaccine counselling on expected adverse effects for individuals previously infected with SARS-CoV-2 prior to vaccination.
Providers should consider additional vaccine counselling on expected adverse effects for individuals previously infected with SARS-CoV-2 prior to vaccination.
My thoughts: If this holds true - this could be dreadful. You are probably more likely to increase your booster frequency following a severe Covid-19 infection, which in turn may increase your likelihood of a serious adverse vaccine event.
This needs some additional study ASAP.
This needs some additional study ASAP.
Loading suggestions...